UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4

Journal of viral hepatitis, 2018-02, Vol.25 (2), p.134-143

2018

Volltextzugriff (PDF)

Thermomechanical fatigue crack growth from laser drilled holes in single crystal nickel based superalloy

International journal of fatigue, 2013-10, Vol.55, p.183-193

2013

Volltextzugriff (PDF)

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

Leukemia, 2010-04, Vol.24 (4), p.699-705

2010

Volltextzugriff (PDF)

Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study

Alimentary pharmacology & therapeutics, 2010-11, Vol.32 (9), p.1102-1112

2010

Volltextzugriff (PDF)

Workplace screening for hand dermatitis: a pilot study

Occupational medicine (Oxford), 2016-01, Vol.66 (1), p.46-49

2016

Volltextzugriff (PDF)

Sofosbuvir plus ribavirin in treatment‐naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India

Journal of viral hepatitis, 2017-05, Vol.24 (5), p.371-379

2017

Volltextzugriff (PDF)

Sustained viral response following treatment with direct acting antiviral agents for chronic hepatitis C and the risk of hepatocellular carcinoma

Journal of hepatology, 2017, Vol.66 (1), p.S491-S492

2017

Volltextzugriff (PDF)

Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in patients coinfected with HCV and HIV-1

Journal of hepatology, 2017, Vol.66 (1), p.S729-S730

2017

Volltextzugriff (PDF)

Ledipasvir/sofosbuvir ± ribavirin for 12 or 24 weeks is safe and effective in children 6–11 years old with chronic hepatitis C infection

Journal of hepatology, 2017, Vol.66 (1), p.S57-S58

2017

Volltextzugriff (PDF)

O056 : Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection

Journal of hepatology, 2015-04, Vol.62, p.S219-S220

2015

Volltextzugriff (PDF)

Integrated Analysis of SOF + RBV or LDV/SOF for the Treatment of Genotype 4 Chronic HCV Infection

Journal of hepatology, 2016, Vol.64 (2), p.S769-S769

2016

Volltextzugriff (PDF)

An in vitro investigation of the cardiovascular effects of the 5-HT4 receptor selective agonists, velusetrag and TD-8954

Vascular pharmacology, 2013-01, Vol.58 (1), p.150-156

2013

Volltextzugriff (PDF)

P1243 SOFOSBUVIR PLUS RIBAVIRIN, AN INTERFERON-FREE REGIMEN, IN THE TREATMENT OF TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH CHRONIC GENOTYPE 4 HCV INFECTION

Journal of hepatology, 2014-04, Vol.60 (1), p.S503-S504

2014

Volltextzugriff (PDF)

Regulation of UNC-130/FOXD-mediated mesodermal patterning in C. elegans

Developmental biology, 2016-08, Vol.416 (2), p.300-311

2016

Volltextzugriff (PDF)

Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors

Alimentary pharmacology & therapeutics, 2004-07, Vol.20 (2), p.223-230

2004

Volltextzugriff (PDF)

Analytical Performance of Multiplexed Screening Test for 10 Antibiotic Resistance Genes from Perianal Swab Samples

Clinical chemistry (Baltimore, Md.), 2016-02, Vol.62 (2), p.353-359

2016

Volltextzugriff (PDF)

The effects of the 5‐HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome

Neurogastroenterology and motility, 2005-04, Vol.17 (2), p.212-221

2005

Volltextzugriff (PDF)

P168 Remdesivir in the treatment of children 28 days to < 18 years of age hospitalised with COVID-19 in the CARAVAN study

Thorax, 2022-11, Vol.77 (Suppl 1), p.A172-A173

2022

Volltextzugriff (PDF)

Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)

Circulation (New York, N.Y.), 2024-03, Vol.149 (13), p.993-1003

2024

Volltextzugriff (PDF)

The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Diabetes care, 2024-04, Vol.47 (4), p.638-645

2024

Volltextzugriff (PDF)

Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Diabetes care, 2024-04, Vol.47 (4), p.610-619

2024

Volltextzugriff (PDF)

Does Emotional Distress Predict Worse Glycemic Control Over Time? Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Diabetes care, 2024-04, Vol.47 (4), p.620-628

2024

Volltextzugriff (PDF)

Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial

Diabetes care, 2024-04, Vol.47 (4), p.562-570

2024

Volltextzugriff (PDF)

Emotional Distress Predicts Reduced Type 2 Diabetes Treatment Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Diabetes care, 2024-04, Vol.47 (4), p.629-637

2024

Volltextzugriff (PDF)

Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Diabetes care, 2024-04, Vol.47 (4), p.603-609

2024

Volltextzugriff (PDF)

1 – 25 von 401

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(357)
Mit Volltextzugriff
(280)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(400)
Japanisch
(44)

Erscheinungsjahr

n.n

Thema

Science & Technology
(224)
Humans
(207)
Life Sciences & Biomedicine
(185)
Female
(128)
Male
(124)
Adult
(101)
Biological And Medical Sciences
(98)
Child
(97)
Adolescent
(95)
Medical Sciences
(88)
Child, Preschool
(82)
Bone Marrow Transplantation
(77)
Middle Aged
(69)
Infant
(55)
Hematology
(44)
Immunology
(39)
Anesthesia. Intensive Care Medicine. Transfusions. Cell Therapy And Gene Therapy
(37)
Animals
(35)
Bone Marrow, Stem Cells Transplantation. Graft Versus Host Reaction
(34)
Transfusions. Complications. Transfusion Reactions. Cell And Gene Therapy
(34)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4

Thermomechanical fatigue crack growth from laser drilled holes in single crystal nickel based superalloy

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study

Workplace screening for hand dermatitis: a pilot study

Sofosbuvir plus ribavirin in treatment‐naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India

Sustained viral response following treatment with direct acting antiviral agents for chronic hepatitis C and the risk of hepatocellular carcinoma

Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in patients coinfected with HCV and HIV-1

Ledipasvir/sofosbuvir ± ribavirin for 12 or 24 weeks is safe and effective in children 6–11 years old with chronic hepatitis C infection

O056 : Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection

Integrated Analysis of SOF + RBV or LDV/SOF for the Treatment of Genotype 4 Chronic HCV Infection

An in vitro investigation of the cardiovascular effects of the 5-HT4 receptor selective agonists, velusetrag and TD-8954

P1243 SOFOSBUVIR PLUS RIBAVIRIN, AN INTERFERON-FREE REGIMEN, IN THE TREATMENT OF TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH CHRONIC GENOTYPE 4 HCV INFECTION

Regulation of UNC-130/FOXD-mediated mesodermal patterning in C. elegans

Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors

Analytical Performance of Multiplexed Screening Test for 10 Antibiotic Resistance Genes from Perianal Swab Samples

The effects of the 5‐HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome

P168 Remdesivir in the treatment of children 28 days to < 18 years of age hospitalised with COVID-19 in the CARAVAN study

Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)

The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Does Emotional Distress Predict Worse Glycemic Control Over Time? Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial

Emotional Distress Predicts Reduced Type 2 Diabetes Treatment Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Suchergebnisse filtern